Advertisement
INSM vs PHAR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a Buy and PHAR is a Buy.
INSM's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for INSM turned positive on October 27, 2026. Looking at past instances where INSM's MACD turned positive, the stock continued to rise in 42 of 52 cases over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on INSM as a result. In 66 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
INSM moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSM advanced for three days, in 201 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
INSM broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INSM entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. INSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.982) is normal, around the industry mean (3.498). P/E Ratio (-27.768) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (23.148) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for PHAR turns positive, indicating new upward trend
PHAR saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 111 similar instances where the indicator turned positive. In 93 of the 111 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PHAR just turned positive on October 20, 2026. Looking at past instances where PHAR's MACD turned positive, the stock continued to rise in 48 of 61 cases over the following month. The odds of a continued upward trend are 79%.
PHAR moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PHAR crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +7.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAR advanced for three days, in 168 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
PHAR broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PHAR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. PHAR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.216) is normal, around the industry mean (3.498). PHAR has a moderately high P/E Ratio (88.107) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.080) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.168) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
INSM | PHAR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 54 | 75 | |
SMR RATING 1..100 | 98 | 86 | |
PRICE GROWTH RATING 1..100 | 57 | 40 | |
P/E GROWTH RATING 1..100 | 54 | 96 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INSM's Valuation (79) in the Biotechnology industry is in the same range as PHAR (95) in the null industry. This means that INSM’s stock grew similarly to PHAR’s over the last 12 months.
INSM's Profit vs Risk Rating (54) in the Biotechnology industry is in the same range as PHAR (75) in the null industry. This means that INSM’s stock grew similarly to PHAR’s over the last 12 months.
PHAR's SMR Rating (86) in the null industry is in the same range as INSM (98) in the Biotechnology industry. This means that PHAR’s stock grew similarly to INSM’s over the last 12 months.
PHAR's Price Growth Rating (40) in the null industry is in the same range as INSM (57) in the Biotechnology industry. This means that PHAR’s stock grew similarly to INSM’s over the last 12 months.
INSM's P/E Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for PHAR (96) in the null industry. This means that INSM’s stock grew somewhat faster than PHAR’s over the last 12 months.
| INSM | PHAR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 72% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 69% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 81% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 75% | 2 days ago 72% |
| Advances ODDS (%) | 2 days ago 69% | 2 days ago 71% |
| Declines ODDS (%) | 9 days ago 76% | 6 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 77% | 2 days ago 78% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INSM’s FA Score shows that 0 FA rating(s) are green while PHAR’s FA Score has 0 green FA rating(s).
- INSM’s FA Score: 0 green, 5 red.
- PHAR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INSM’s TA Score shows that 4 TA indicator(s) are bullish while PHAR’s TA Score has 5 bullish TA indicator(s).
- INSM’s TA Score: 4 bullish, 5 bearish.
- PHAR’s TA Score: 5 bullish, 5 bearish.
Price Growth
INSM (@Biotechnology) experienced а +14.41% price change this week, while PHAR (@Biotechnology) price change was +2.24% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
INSM is expected to report earnings on Feb 25, 2027.
PHAR is expected to report earnings on Mar 18, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PHAR and
Correlation & Price change
A.I.dvisor indicates that over the last year, PHAR has been loosely correlated with TRDA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAR jumps, then TRDA could also see price increases.
| Ticker / NAME | Correlation To PHAR | 1D Price Change % | ||
|---|---|---|---|---|
| PHAR | 100% | +0.46% | ||
| TRDA - PHAR | 44% Loosely correlated | +11.94% | ||
| ENGN - PHAR | 43% Loosely correlated | -5.65% | ||
| LKFT - PHAR | 36% Loosely correlated | -0.33% | ||
| INSM - PHAR | 34% Loosely correlated | +2.92% | ||
| LGND - PHAR | 33% Loosely correlated | +0.00% | ||
More | ||||